Main Menu


Publications Highlights View all by category

Types of Publications

Journal Articles

Campbell, J., Ryan, C., Brough, R., Bajrami, I., Pemberton, H., Chong, I., Costa-Cabral, S., Frankum, J., Gulati, A., Holme, H., et al. (2016). Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell reports, Vol.14(10), pp. 2490-2501.  show abstract  full text

Workman, P., Clarke, P.A. & Al-Lazikani, B. (2016). Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget, Vol.7(4), pp. 3658-3661.  show abstract  full text

Tym, J.E., Mitsopoulos, C., Coker, E.A., Razaz, P., Schierz, A.C., Antolin, A.A. & Al-Lazikani, B. (2016). canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic acids research, Vol.44(D1), pp. 938-943.  show abstract  full text

Pearl, L.H., Schierz, A.C., Ward, S.E., Al-Lazikani, B. & Pearl, F.M. (2015). Therapeutic opportunities within the DNA damage response. Nature reviews cancer, Vol.15(3), pp. 166-180.  show abstract

Mitsopoulos, C., Schierz, A.C., Workman, P. & Al-Lazikani, B. (2015). Distinctive Behaviors of Druggable Proteins in Cellular Networks. Plos computational biology, Vol.11(12), pp. e1004597-e1004597.  show abstract  full text

Al-Lazikani, B., Banerji, U. & Workman, P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nature biotechnology, Vol.30(7), pp. 679-692.  show abstract

Patel, M.N., Halling-Brown, M.D., Tym, J.E., Workman, P. & Al-Lazikani, B. (2012). Objective assessment of cancer genes for drug discovery. Nature reviews drug discovery, Vol.12(1), pp. 35-50.  show abstract

Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012). ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic acids research, Vol.40(D1), pp. 1100-1107.  show abstract  full text

Halling-Brown, M.D., Bulusu, K.C., Patel, M.N., Tym, J.E. & Al-Lazikani, B. (2012). canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic acids research, Vol.40(D1), pp. 947-956.  show abstract  full text

Berriman, M., Haas, B.J., LoVerde, P.T., Wilson, R.A., Dillon, G.P., Cerqueira, G.C., Mashiyama, S.T., Al-Lazikani, B., Andrade, L.F., Ashton, P.D., et al. (2009). The genome of the blood fluke Schistosoma mansoni. Nature, Vol.460(7253), pp. 352-U65.  show abstract  full text

Aguero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F.S., Campbell, R.K., Carmona, S., Carruthers, I.M., Chan, A.W., Chen, F., et al. (2008). INNOVATION Genomic-scale prioritization of drug targets: the TDR Targets database. Nat rev drug discov, Vol.7(11), pp. 900-907.  show abstract

Overington, J.P., Al-Lazikani, B. & Hopkins, A.L. (2006). Opinion - How many drug targets are there?. Nat rev drug discov, Vol.5(12), pp. 993-996.  show abstract

In this section

Professional activities Publications

Division of Cancer Therapeutics

The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments and biomarkers.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.